| Spyre Therapeutics Announces Grants of Inducement Awards | 11/01 16:44 | prnewswire.com |
| Spyre Therapeutics to Participate in Upcoming November Investor Conferences | 10/30 16:05 | prnewswire.com |
| Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations | 10/14 08:00 | prnewswire.com |
| Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting | 10/01 15:29 | seekingalpha.com |
| Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer | 10/01 08:00 | prnewswire.com |
| Spyre Therapeutics to Participate in Upcoming Investor Conference | 09/10 16:47 | prnewswire.com |
| Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update | 08/07 16:05 | prnewswire.com |
| Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease | 06/18 07:30 | prnewswire.com |